Qatar Breast Cancer Therapeutics Market Report 2022 to 2030

Qatar Breast Cancer Therapeutics Market Analysis

$ 3999

The Qatar breast cancer therapeutics market is projected to grow from $73 Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022-2030. The presence of specialized cancer treatment facilities and easily accessible breast cancer treatment in Qatar are the main market drivers of growth. The market is segmented by therapy, by cancer type, and by distribution channel. Some of the leading companies in Qatar's breast cancer therapeutics market are Al Sawari Medical, Bristol-Myers Squibb, and Eli Lilly.

ID: IN10QAPH031 CATEGORY: Pharmaceuticals GEOGRAPHY: Qatar AUTHOR: Parul Choudhary

Buy Now

Qatar Breast Cancer Therapeutics Market Executive Analysis

The Qatar breast cancer therapeutics market size is at around $73 Mn in 2022 and is projected to reach $xx Mn in 2030, exhibiting a CAGR of xx% during the forecast period. Qatar's current healthcare expenditure (CHE) is predicted to increase from $5.8 Bn in 2017 to $6.6 Bn in 2022 at an average annual growth rate of 2.2%. Modest population growth is anticipated by moderate growth. Spending on other healthcare services is anticipated to expand at a slow annualized average of 2.2%. In the first half of 2022, GDP growth was 4.4%, and in 2023, it is forecast to slow.

Qatar has one of the highest incidence and fatality rates for breast cancer when compared to other Middle Eastern nations. Breast cancer is the most common type of new cancer cases in Qatar in 2020, making up 14.7% of all new cancer cases and 37.5% of new cancer cases in women. Age-adjusted mortality rates for breast cancer are lower when the disease is discovered early. When women receive screening tests, it's possible that early-stage cancers are identified, allowing for quicker treatment and ultimately increasing survival rates. Gene expression profiling, a genetic microarray examination of genetic transcriptional changes between normal and malignant cells, was introduced by Hamad Medical Corporation (HMC) in Qatar to further the personalization of care. The Oncotype Dx, a 21-gene recurrence score, is one such gene profile used at HMC to help determine whether women with node-negative, hormone-receptor-positive breast cancer would benefit from combining chemotherapy with conventional hormonal therapy. The Halsted radical mastectomy, breast-conserving surgery, and more recent, more sophisticated oncoplastic surgical techniques of breast conservation and breast reconstruction represent a substantial advancement in surgical care.

qatar breast cancer therapeutics market analysis

Market Dynamics

Market Growth Drivers

The Qatari government's significant investments in healthcare facilities and services including the creation of specialized cancer treatment facilities and the improvement of healthcare service accessibility will drive the Qatar breast cancer therapeutics market. As more people have access to and can afford these therapies, rising healthcare costs in Qatar may spur market expansion for Qatar breast cancer therapeutics.

Market Restraints

Breast cancer treatments can be costly, and those without sufficient insurance coverage may find it difficult to finance them. The amount of breast cancer clinical trials accessible may be hampered by Qatar's very small population thereby impeding the growth of Qatar's breast cancer therapeutics market.

Competitive Landscape

Key Players

Techcare Qatar (QAT)
Aspirom (QAT)
Al Sawari Medical (QAT)
Bristol-Myers Squibb
Eli Lilly
Halozyme
Merck

Healthcare Policies and Regulatory Landscape

The Qatar National Health Insurance Company (QNHIC), the nation's national health insurance program, provides healthcare coverage for breast cancer treatments in Qatar. The cost of prescription drugs and other relevant therapies is also covered by the QNHIC. Breast reconstruction surgery is also covered, which is something that other health insurance plans may not always do. The QNHIC uses a tiered reimbursement structure, so the amount of reimbursement a patient receives may differ based on the kind of care they receive and the provider. For instance, while some treatments can be completely covered, others might have a co-pay or deductible. Additionally, Qatar boasts a number of specialty cancer centers, like the Hamad Medical Corporation's (HMC) Breast Cancer Centre, which offers complete breast cancer diagnosis, care, and support. Patients receive the greatest care possible at these facilities because they feature advanced equipment and qualified medical staff.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Breast Cancer Therapeutics Segmentation

By Therapy (Revenue, USD Billion):

Radiation Therapy
- Targeted Therapy
  - Ribociclib
  - Abemaciclib
  - Afinitor
  - Everolimus
  - Trastuzumab
  - Olaparib
  - Ado-Trastuzumab Emtansine
  - Palbociclib
  - Pertuzumab
  - Herceptin
  - Tykerb (Lapatinib)
  - Others
Hormonal Therapy
- Selective Estrogen Receptor Modulators (SERMs)
- Aromatase Inhibitors
- Estrogen Receptor Downregulators (ERDs)
Chemotherapy
- Taxanes
- Anthracyclines
- Anti-metabolites
- Alkylating Agents
Immunotherapy

By Cancer Type (Revenue, USD Billion):

Hormone Receptor
HER+

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.